Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Accumulated Expenses (2020 - 2025)

Maravai Lifesciences Holdings has reported Accumulated Expenses over the past 6 years, most recently at $36.6 million for Q4 2025.

  • Quarterly results put Accumulated Expenses at $36.6 million for Q4 2025, down 7.6% from a year ago — trailing twelve months through Dec 2025 was $36.6 million (down 7.6% YoY), and the annual figure for FY2025 was $36.6 million, down 7.6%.
  • Accumulated Expenses for Q4 2025 was $36.6 million at Maravai Lifesciences Holdings, down from $48.1 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for MRVI hit a ceiling of $70.1 million in Q1 2023 and a floor of $24.8 million in Q2 2021.
  • Median Accumulated Expenses over the past 5 years was $42.2 million (2022), compared with a mean of $44.0 million.
  • Biggest five-year swings in Accumulated Expenses: soared 116.18% in 2023 and later plummeted 49.47% in 2024.
  • Maravai Lifesciences Holdings' Accumulated Expenses stood at $34.6 million in 2021, then surged by 54.37% to $53.4 million in 2022, then increased by 12.86% to $60.2 million in 2023, then plummeted by 34.3% to $39.6 million in 2024, then decreased by 7.6% to $36.6 million in 2025.
  • The last three reported values for Accumulated Expenses were $36.6 million (Q4 2025), $48.1 million (Q3 2025), and $50.2 million (Q2 2025) per Business Quant data.